Takeda Pharmaceutical Co’s logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon
Mosquito-borne dengue can cause hemorrhagic fever and infects an estimated 100 to 400 million people yearly, although over 80 percent of cases are mild or asymptomatic, the WHO says. Takeda Pharmaceutical said its vaccine, marketed as Qdenga, was given regulatory approval by the European Commission on Thursday for people aged four and above, regardless of their virus exposure history.
Another dengue vaccine, Dengvaxia — the world’s first against the disease — is already available in the European Union, but only for those who have had a previously confirmed infection. Dengvaxia became the subject of controversy in 2019 when the Philippines banned it over safety concerns, claims which its maker, French pharmaceutical giant Sanofi, denies.The number of reported dengue cases has increased more than eightfold in the last two decades, according to the World Health Organisation, which says “about half of the world’s population now at risk”.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: GuardianNigeria - 🏆 1. / 94 Read more »